Systematic Review Software Pricing & Feature Tracker (2026)
Prices below come only from each vendor's own pricing page, with the date we checked. We do not take prices from third-party review sites, because those are frequently out of date in the direction that flatters the tool.
Plans an individual can buy directly
| Tool | Plan | Price | Intended buyer | Stated limits |
|---|---|---|---|---|
| ASReview LAB | Open source | Free | individual | No licence fee; runs locally |
| Rayyan | Free | Free | individual | 3 active reviews, 2 free reviewers, duplicate detection, AI predictions |
| Rayyan | Essential | US$4.99/month (billed annually) | individual | PRISMA diagrams, 5 free reviewers, auto-resolve duplicates |
| Rayyan | Advanced | US$8.33/month (billed annually) | team | 9 active reviews, 10 free reviewers, PICO data extraction |
| Covidence | Single | US$339/year | individual | One review, unlimited collaborators |
| Covidence | Package | US$907/year | team | Up to 3 reviews, unlimited collaborators |
| Covidence | Organizations | Custom quote | institution | Custom quote; unlimited reviews and users |
The thing most comparisons leave out
The headline price is rarely what decides the purchase. What decides it is the limit attached to it — how many reviews a plan covers, how many reviewers you can invite without paying more, and how large a trial you get before committing.
Those limits also determine what we ourselves can test. A record-limited individual trial makes a full-corpus benchmark run impossible, so the affected tool carries an empty performance cell and a stated reason rather than an estimate. We would rather show you the boundary than paper over it.
Sources
- ASReview LAB —https://asreview.nl/checked 2026-08-16
- Rayyan —https://www.rayyan.ai/checked 2026-08-16
- Covidence —https://www.covidence.org/checked 2026-08-16